Laboratory Parameters in Adolescent Patients Aged 12–17 With Moderate-to-Severe Atopic Dermatitis Treated With Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial. J of Skin 2024, 8 (1), s323. https://doi.org/10.25251/skin.8.supp.323.